Other languages Mind Medicine (MindMed) Inc.

Equities

MNMD

CA60255C8850

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
9.07 ^USD	+6.83%		-5.62%	+147.81%

May. 13	Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating	MT
May. 08	Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder	Mar. 08
Sector Update: Health Care Stocks Gain Late Afternoon	Mar. 07
Sector Update: Health Care Stocks Stronger in Afternoon Trading	Mar. 07
Mind Medicine Gets FDA Breakthrough for Anxiety Treatment, Sees $175 Million in Proceeds From Stock Offerings; Shares Jump	Mar. 07
Mind Medicine Inc. Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data from Phase 2B Study of MM120 for Generalized Anxiety Disorder	Mar. 07
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Mind Medicine Inc. Provides Anticipated Production Milestones for 2024	Jan. 08
Mind Medicine Says MM-120 Shows Significant Dose-Dependent Improvements in Phase 2b Trial on Anxiety Disorder	Dec. 14
Mind Medicine Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder	Dec. 14
Mind Medicine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Mind Medicine Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder	23-10-24
Mind Medicine Completes Enrollment and Dosing in Study Mmed008	23-09-12
Mind Medicine Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Mind Medicine Inc Issues the Preliminary Voting Results Provided by First Coast Results, Inc	23-06-27
Mind Medicine Inc. Elects David Gryska to the Board of Directors	23-06-21
Mind Medicine Inc. Provides Overview of Clinical Progress	23-06-20
FCM MM Holdings Posts Material on Social Media Platforms	23-06-16
FCM MM Holdings Provides Information to Shareholders of Mind Medicine	23-06-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Mind Medicine (MindMed) Inc.

Equities

MNMD

CA60255C8850

Other languages

Filters